Background: Homozygous mutations in acid-labile subunit (IGFALS) gene result in short stature, very low circulating levels of acid-labile subunit (ALS), insulin growth factor 1 (IGF1) and insulin growth factor binding protein 3 (IGFBP3) and a poor response to growth hormone (GH). The impact of IGFALS mutations heterozygosity on growth is unknown. Patient and Methods: We describe a 10-year-old girl with severe short stature (height -3.2 SDS), heterozygous for a new IGFALS mutation. Results: The girl showed low circulating IGF1, IGFBP3 and ALS levels and normal GH secretion. We found a novel heterozygous frameshift IGFALS mutation (c.1283delA, p.Gln428Argfs*14). Size-exclusion chromatography showed a reduction of the IGF1, IGFBP3 and ALS 150-kDa ternary complex (by about 55%) compared to a control. An IGF-1 generation test, with two different GH dosages, showed a good response in term of increase in IGF1 and in formation of the ternary complex at size-exclusion chromatography. Clinical response after 6 months of therapy with GH was satisfactory (height velocity increased from 3 to 8 cm/year). Conclusion: We suggest that (1) heterozygous IGFALS mutations can be responsible for a subset of patients with severe short stature (below -2.5 SDS), low IGF1 (below -2 SDS) and normal GH secretion, and (2) the identification by IGFALS molecular screening of this subset of patients could help in the administration of the appropriate therapy.

1.
Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F, et al: Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 2010;467:832-838.
2.
Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P: Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res 2008;18:89-110.
3.
Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT: The acid-labile subunit of the 150-kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001;170:63-70.
4.
Janosi JB, Ramsland PA, Mott MR, Firth SM, Baxter RC, Delhanty PJ: The acid-labile subunit of the serum insulin-like growth factor-binding protein complexes. Structural determination by molecular modeling and electron microscopy. J Biol Chem 1999;274:23328-23332.
5.
David A, Kelley LA, Sternberg MJ: A new structural model of the acid-labile subunit: pathogenetic mechanisms of short stature-causing mutations. J Mol Endocrinol 2012;49:213-220.
6.
Domené HM, Bengolea SV, Martínez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich JJ, Jasper HG: Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004;350:570-577.
7.
Domené HM, Hwa V, Jasper HG, Rosenfeld RG: Acid-labile subunit deficiency. Best Pract Res Clin Endocrinol Metab 2011;25:101-113.
8.
Fofanova-Gambetti OV, Hwa V, Wit JM, Domené H, Argente J, Bang P, Hogler W, Kirsch S, Pihoker C, Chiu HK, Cohen L, Jacobsen C, Jasper H, Haeusler G, Campos-Barros A, Gallego-Gómez E, Gracia-Bouthelier R, van Duyvenvoorde HA, Pozo J, Rosenfeld RG: Impact of heterozygosity for acid-labile subunit (IGFALS) gene mutations on stature: results from the International ALS Consortium. J Clin Endocrinol Metab 2010;95:4184-4191.
9.
David A, Miraki-Moud F, Metherell AL, Jones J, Edwards R, Camacho-Hübner C, Johnston BL, Savage OM, Clark JLA: Heterozygous defect of the acid-labile subunit gene in idiopathic short stature. Horm Res 2008;70(suppl 1):31.
10.
Scaglia PA, Domené HM, Martínez AS, Keselman AC, Pipman VR, Bengolea SV, Karabatas LM, Lescano EM, Ropelato MG, Ballerini MG, Heinrich JJ, Jasper HG: Heterozygous IGFALS gene mutations are present in both idiopathic short stature and in normal children: impact on height and acid-labile subunit levels. Horm Res 2009;72(suppl. 3): 246.
11.
Wit JM, van Duyvenvoorde HA, Scheltinga SA, de Bruin S, Hafkenscheid L, Kant SG, Ruivenkamp CA, Gijsbers AC, van Doorn J, Feigerlova E, Noordam C, Walenkamp MJ, Claahsen-van de Grinten H, Stouthart P, Bonapart IE, Pereira AM, Gosen J, Delemarre-van de Waal HA, Hwa V, Breuning MH, Domené HM, Oostdijk W, Losekoot M: Genetic analysis of short children with apparent growth hormone insensitivity. Horm Res Paediatr 2012;77:320-333.
12.
Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, Cerutti F, Gargantini L, Greggio N, Tonini G, Cicognani A: Italian cross-sectional growth charts for height, weight and BMI (2 to 20 years). J Endocrinol Invest 2006;29:581-593.
13.
Walenkamp MJE, Wit JM: Genetic disorders in the growth hormone-IGF-I axis. Horm Res 2006;66:221-230.
14.
Baxter RC, Martin JL: Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. Proc Natl Acad Sci USA 1989;86:6898-6902.
15.
Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, Rosenfeld RG: Total absence of functional acid-labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 2006;91:1826-1831.
16.
Van Duyvenvoorde HA, Kempers MJ, Twickler TB, van Doorn J, Gerver WJ, Noordam C, Losekoot M, Karperien M, Wit JM, Hermus AR: Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur J Endocrinol 2008;159:113-120.
17.
Collett-Solberg PF, Misra M: Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society: The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab 2008;93:10-18.
18.
Coutant R, Dörr HG, Gleeson H, Argente J: Diagnosis of endocrine disease: limitations of the IGF1 generation test in children with short stature. Eur J Endocrinol 2012;166:351-357.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.